Loading...

Oventus Medical

ASX:OVN
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OVN
ASX
A$23M
Market Cap
  1. Home
  2. AU
  3. Healthcare
Company description

Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of sleep apnoea and snoring in Australia. The last earnings update was 63 days ago. More info.


Add to Portfolio Compare Print
  • Oventus Medical has significant price volatility in the past 3 months.
OVN Share Price and Events
7 Day Returns
-6.5%
ASX:OVN
4.1%
AU Medical Equipment
-0%
AU Market
1 Year Returns
-46.3%
ASX:OVN
-3.3%
AU Medical Equipment
4.9%
AU Market
OVN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Oventus Medical (OVN) -6.5% -23.2% -29.5% -46.3% - -
AU Medical Equipment 4.1% 0.7% 0.8% -3.3% 38.7% 103.7%
AU Market -0% 1.4% 6.5% 4.9% 18.2% 4.8%
1 Year Return vs Industry and Market
  • OVN underperformed the Medical Equipment industry which returned -3.3% over the past year.
  • OVN underperformed the Market in Australia which returned 4.9% over the past year.
Price Volatility
OVN
Industry
5yr Volatility vs Market

Value

 Is Oventus Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Oventus Medical. This is due to cash flow or dividend data being unavailable. The share price is A$0.215.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Oventus Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Oventus Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:OVN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.06
ASX:OVN Share Price ** ASX (2019-04-17) in AUD A$0.22
Australia Medical Equipment Industry PE Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 33.38x
Australia Market PE Ratio Median Figure of 544 Publicly-Listed Companies 16.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Oventus Medical.

ASX:OVN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:OVN Share Price ÷ EPS (both in AUD)

= 0.22 ÷ -0.06

-3.37x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oventus Medical is loss making, we can't compare its value to the AU Medical Equipment industry average.
  • Oventus Medical is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Oventus Medical's expected growth come at a high price?
Raw Data
ASX:OVN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.37x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Oceania Medical Equipment Industry PEG Ratio Median Figure of 5 Publicly-Listed Medical Equipment Companies 2.62x
Australia Market PEG Ratio Median Figure of 360 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Oventus Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Oventus Medical's assets?
Raw Data
ASX:OVN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.11
ASX:OVN Share Price * ASX (2019-04-17) in AUD A$0.22
Australia Medical Equipment Industry PB Ratio Median Figure of 30 Publicly-Listed Medical Equipment Companies 2.72x
Australia Market PB Ratio Median Figure of 1,676 Publicly-Listed Companies 1.67x
ASX:OVN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:OVN Share Price ÷ Book Value per Share (both in AUD)

= 0.22 ÷ 0.11

1.98x

* Primary Listing of Oventus Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Oventus Medical is good value based on assets compared to the AU Medical Equipment industry average.
X
Value checks
We assess Oventus Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Oventus Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Oventus Medical expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oventus Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
13.2%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Oventus Medical expected to grow at an attractive rate?
  • Unable to compare Oventus Medical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Oventus Medical's earnings growth to the Australia market average as no estimate data is available.
  • Unable to compare Oventus Medical's revenue growth to the Australia market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ASX:OVN Future Growth Rates Data Sources
Data Point Source Value (per year)
Australia Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 13.2%
Australia Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 6.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:OVN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:OVN Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -4 -7
2018-09-30 0 -4 -6
2018-06-30 0 -5 -6
2018-03-31 0 -5 -6
2017-12-31 0 -5 -6
2017-09-30 0 -5 -6
2017-06-30 0 -6 -7
2017-03-31 1 -5 -6
2016-12-31 1 -4 -5
2016-09-30 1 -3 -4
2016-06-30 1 -2 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Oventus Medical is high growth as no earnings estimate data is available.
  • Unable to determine if Oventus Medical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:OVN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Oventus Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:OVN Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.06
2018-09-30 -0.06
2018-06-30 -0.06
2018-03-31 -0.07
2017-12-31 -0.08
2017-09-30 -0.08
2017-06-30 -0.09
2017-03-31 -0.09
2016-12-31 -0.08
2016-09-30 -0.07
2016-06-30 -0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Oventus Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Oventus Medical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Oventus Medical's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Oventus Medical's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Oventus Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Oventus Medical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Oventus Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Oventus Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Oventus Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Oventus Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Oventus Medical's 1-year growth to the AU Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Oventus Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Oventus Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:OVN Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.29 -6.76 6.18 0.27
2018-09-30 0.28 -6.32 5.70 0.27
2018-06-30 0.27 -5.87 5.22 0.27
2018-03-31 0.30 -6.08 5.87 0.27
2017-12-31 0.32 -6.28 6.10 0.25
2017-09-30 0.39 -6.40 5.88 0.25
2017-06-30 0.45 -6.51 5.66 0.24
2017-03-31 0.54 -5.60 4.72 0.12
2016-12-31 0.63 -4.68 3.78
2016-09-30 0.58 -3.51 2.91
2016-06-30 0.54 -2.34 2.04
2015-06-30 0.06 -0.18 0.16
2014-06-30 -0.01 0.01

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Oventus Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Oventus Medical has efficiently used its assets last year compared to the AU Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Oventus Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Oventus Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Oventus Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Oventus Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Oventus Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Oventus Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Oventus Medical has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Oventus Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Oventus Medical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Oventus Medical Company Filings, last reported 3 months ago.

ASX:OVN Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 11.52 0.00 7.00
2018-09-30 11.52 0.00 7.00
2018-06-30 15.13 0.00 9.89
2018-03-31 15.13 0.00 9.89
2017-12-31 18.06 0.00 12.86
2017-09-30 18.06 0.00 12.86
2017-06-30 12.89 0.00 8.65
2017-03-31 12.89 0.00 8.65
2016-12-31 10.16 0.00 6.23
2016-09-30 10.16 0.00 6.23
2016-06-30 1.94 0.76 0.25
2015-06-30 0.15 0.55 0.04
2014-06-30
  • Oventus Medical has no debt.
  • Oventus Medical currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Oventus Medical has sufficient cash runway for 1.1 years based on current free cash flow.
  • Oventus Medical has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 4.6% each year.
X
Financial health checks
We assess Oventus Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Oventus Medical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Oventus Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Oventus Medical dividends.
If you bought A$2,000 of Oventus Medical shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Oventus Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Oventus Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:OVN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Oceania Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1.7%
Australia Market Average Dividend Yield Market Cap Weighted Average of 417 Stocks 4.3%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.6%
Australia Bottom 25% Dividend Yield 25th Percentile 2.5%
Australia Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Oventus Medical has not reported any payouts.
  • Unable to verify if Oventus Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Oventus Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Oventus Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Oventus Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Oventus Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Oventus Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Oventus Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Hart
COMPENSATION A$432,030
TENURE AS CEO 0.7 years
CEO Bio

Dr. Christopher Patrick Hart, also known as Chris, has been Chief Executive Officer and Managing Director of Oventus Medical Limited since September 2018. Dr. Hart is the Co-Founder of Oventus Medical Limited and served as its Clinical Director until September 2018. Dr. Hart has been an Executive Director of Oventus Medical Limited since September 23, 2015. Prior to establishing Oventus, Dr. Hart owned and managed a multi-site national dental practice, training institute and management consultancy, which he sold to private equity investors. He also acts as an adviser to various bodies within the dental industry as well as the health care sector more broadly on the commercial aspects of health care delivery. Dr. Hart graduated from the University of Queensland in 1998 with a Bachelor of Dental Science with honours and a Bachelor of Science in Biochemistry. He has studied at Cambridge University where he graduated with a Master of Philosophy in Biomedical Science in 1999.

CEO Compensation
  • Chris's compensation has increased whilst company is loss making.
  • Chris's remuneration is about average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Oventus Medical management team in years:

1.3
Average Tenure
  • The average tenure for the Oventus Medical management team is less than 2 years, this suggests a new team.
Management Team

Chris Hart

TITLE
Co-Founder
COMPENSATION
A$432K
TENURE
0.7 yrs

Neil Anderson

TITLE
Co-Founder
COMPENSATION
A$421K
AGE
59

Daniel Parry

TITLE
Chief Financial & Operations Officer
COMPENSATION
A$202K
TENURE
1.3 yrs

Robin Randolph

TITLE
Vice President Marketing & Operations of North America
COMPENSATION
A$229K

Steve Denaro

TITLE
Company Secretary & Director
COMPENSATION
A$29K
TENURE
3.5 yrs

Greg Eaton

TITLE
Vice President Sales
Board of Directors Tenure

Average tenure and age of the Oventus Medical board of directors in years:

0.6
Average Tenure
63.5
Average Age
  • The average tenure for the Oventus Medical board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mel Bridges

TITLE
Non-Executive Chairman
COMPENSATION
A$87K
AGE
68
TENURE
3.6 yrs

Chris Hart

TITLE
Co-Founder
COMPENSATION
A$432K
TENURE
3.6 yrs

Neil Anderson

TITLE
Co-Founder
COMPENSATION
A$421K
AGE
59
TENURE
3.6 yrs

Steve Denaro

TITLE
Company Secretary & Director
COMPENSATION
A$29K

Sue MacLeman

TITLE
Independent Non-Executive Director
COMPENSATION
A$62K
AGE
54
TENURE
3.4 yrs

Lee Surkin

TITLE
Member of Medical Technology Advisory Board
TENURE
0.6 yrs

Richard Bogan

TITLE
Member of Medical Technology Advisory Board
AGE
72
TENURE
0.6 yrs

Jerry Kram

TITLE
Member of Medical Technology Advisory Board
TENURE
0.6 yrs

Mark Hickey

TITLE
Member of Medical Technology Advisory Board
TENURE
0.6 yrs

Mark Rasmus

TITLE
Member of Medical Technology Advisory Board
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Oventus Medical insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
10. Mar 19 Buy Susan MacLeman Individual 05. Mar 19 05. Mar 19 16,495 A$0.30 A$4,914
27. Feb 19 Buy Parma Corporation Pty. Ltd. Company 25. Feb 19 26. Feb 19 16,831 A$0.30 A$5,077
27. Feb 19 Buy Melvyn Bridges Individual 25. Feb 19 26. Feb 19 99,453 A$0.31 A$30,416
25. Feb 19 Buy Melvyn Bridges Individual 19. Feb 19 22. Feb 19 70,000 A$0.30 A$20,652
25. Feb 19 Buy Parma Corporation Pty. Ltd. Company 19. Feb 19 22. Feb 19 50,216 A$0.30 A$14,846
23. Jul 18 Buy Melvyn Bridges Individual 20. Jul 18 20. Jul 18 91,800 A$0.33 A$29,999
19. Jun 18 Buy Parma Corporation Pty. Ltd. Company 14. Jun 18 18. Jun 18 27,625 A$0.36 A$10,000
19. Jun 18 Buy Melvyn Bridges Individual 14. Jun 18 18. Jun 18 100,125 A$0.36 A$35,049
X
Management checks
We assess Oventus Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Oventus Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Oventus Medical Limited (ASX:OVN): Time For A Financial Health Check

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is OVN right in choosing financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

Do Insiders Own Shares In Oventus Medical Limited (ASX:OVN)?

The big shareholder groups in Oventus Medical Limited (ASX:OVN) have power over the company. … With a market capitalization of AU$29m, Oventus Medical is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Oventus Medical

Simply Wall St -

What Investors Should Know About Oventus Medical Limited's (ASX:OVN) Financial Strength

Oventus Medical Limited (ASX:OVN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is OVN will have to follow strict debt obligations which will reduce its financial flexibility. … Is financial flexibility worth the lower cost of capital.

Simply Wall St -

Company Info

Description

Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of sleep apnoea and snoring in Australia. It offers O2Vent W, a winged-style device to stabilize the jaw; O2Vent T devices that titrate lower jaw forward; O2Vent Mono, a device that advances the lower jaw to a fixed position; and O2Vent nylon and O2Vent ONEPAP appliances. The company was incorporated in 2015 and is headquartered in Indooroopilly, Australia.

Details
Name: Oventus Medical Limited
OVN
Exchange: ASX
Founded: 2015
A$22,776,930
105,939,212
Website: http://www.o2vent.com
Address: Oventus Medical Limited
1 Swann Road,
Suite 1,
Indooroopilly,
Queensland, 4068,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX OVN Ordinary Shares Australian Securities Exchange AU AUD 19. Jul 2016
CHIA OVN Ordinary Shares Chi-X Australia AU AUD 19. Jul 2016
Number of employees
Current staff
Staff numbers
0
Oventus Medical employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 10:36
End of day share price update: 2019/04/17 00:00
Last earnings filing: 2019/02/17
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.